Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
32650 | 105 | 34.9 | 88% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
876 | 10798 | P GLYCOPROTEIN//MULTIDRUG RESISTANCE//ABCG2 |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | RHEUMATOLOTA KU | Address | 2 | 33% | 4% | 4 |
2 | MDR I | Author keyword | 1 | 100% | 2% | 2 |
3 | DANINI HOSP | Address | 1 | 50% | 1% | 1 |
4 | INEFFECTIVE THERAPY | Author keyword | 1 | 50% | 1% | 1 |
5 | MED INFORMAT NETWORK | Address | 1 | 50% | 1% | 1 |
6 | RADIOLOGIC RESULTS | Author keyword | 1 | 50% | 1% | 1 |
7 | RADIOPHARMACEUT SCI PSI ETH USZ | Address | 1 | 50% | 1% | 1 |
8 | RHEUMATOL AGEN DIS | Address | 1 | 50% | 1% | 1 |
9 | RHEUMATOLSHINJYUKU KU | Address | 1 | 50% | 1% | 1 |
10 | HOSP GEN REG 36 | Address | 0 | 33% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | MDR I | 1 | 100% | 2% | 2 | Search MDR+I | Search MDR+I |
2 | INEFFECTIVE THERAPY | 1 | 50% | 1% | 1 | Search INEFFECTIVE+THERAPY | Search INEFFECTIVE+THERAPY |
3 | RADIOLOGIC RESULTS | 1 | 50% | 1% | 1 | Search RADIOLOGIC+RESULTS | Search RADIOLOGIC+RESULTS |
4 | ATDC5 CELL | 0 | 25% | 1% | 1 | Search ATDC5+CELL | Search ATDC5+CELL |
5 | CARTILAGE MATRIX DEGRADATION | 0 | 25% | 1% | 1 | Search CARTILAGE+MATRIX+DEGRADATION | Search CARTILAGE+MATRIX+DEGRADATION |
6 | INTERLEUKIN ALPHA | 0 | 25% | 1% | 1 | Search INTERLEUKIN+ALPHA | Search INTERLEUKIN+ALPHA |
7 | CALCEIN ASSAY | 0 | 20% | 1% | 1 | Search CALCEIN+ASSAY | Search CALCEIN+ASSAY |
8 | MTSS | 0 | 14% | 1% | 1 | Search MTSS | Search MTSS |
9 | ABCB1 MDR1 | 0 | 11% | 1% | 1 | Search ABCB1+MDR1 | Search ABCB1+MDR1 |
10 | GRAVES BASEDOW DISEASE | 0 | 11% | 1% | 1 | Search GRAVES+BASEDOW+DISEASE | Search GRAVES+BASEDOW+DISEASE |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | I MDR I | 7 | 57% | 8% | 8 |
2 | RHEUMATIC AUTOIMMUNE DISORDERS | 2 | 38% | 5% | 5 |
3 | INFLAMMATORY CYTOKINE LEVELS | 2 | 50% | 3% | 3 |
4 | ANTIARTHRITIC PROPERTIES | 1 | 38% | 3% | 3 |
5 | ANTI INTERLEUKIN 1 | 1 | 50% | 1% | 1 |
6 | INTERLEUKIN 6 INDUCED DIFFERENTIATION | 1 | 50% | 1% | 1 |
7 | INTERLEUKIN 1 SYNTHESIS | 0 | 33% | 1% | 1 |
8 | BINDING PROTEIN YB 1 | 0 | 13% | 2% | 2 |
9 | AMELIORATES JOINT DISEASE | 0 | 13% | 2% | 2 |
10 | INDUCED LYMPHOCYTOLYSIS | 0 | 20% | 1% | 1 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease | 2012 | 4 | 16 | 38% |
Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials | 2010 | 9 | 20 | 40% |
Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis | 2007 | 50 | 57 | 25% |
P-Glycoprotein and Drug Resistance in Systemic Autoimmune Diseases | 2014 | 3 | 70 | 23% |
MDR-ABC transporters: biomarkers in rheumatoid arthritis | 2013 | 6 | 117 | 10% |
Tacrolimus in rheumatoid arthritis | 2006 | 9 | 30 | 33% |
A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis | 2005 | 26 | 75 | 17% |
P-glycoprotein in autoimmune rheumatic diseases | 2015 | 0 | 41 | 34% |
Relevance of multidrug resistance 1 and P-glycoprotein to drug resistance in patients with systemic lupus erythematosus | 2007 | 5 | 14 | 21% |
Mechanisms and therapeutic potential of inhibiting drug efflux transporters | 2015 | 0 | 123 | 7% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | RHEUMATOLOTA KU | 2 | 33% | 3.8% | 4 |
2 | DANINI HOSP | 1 | 50% | 1.0% | 1 |
3 | MED INFORMAT NETWORK | 1 | 50% | 1.0% | 1 |
4 | RADIOPHARMACEUT SCI PSI ETH USZ | 1 | 50% | 1.0% | 1 |
5 | RHEUMATOL AGEN DIS | 1 | 50% | 1.0% | 1 |
6 | RHEUMATOLSHINJYUKU KU | 1 | 50% | 1.0% | 1 |
7 | HOSP GEN REG 36 | 0 | 33% | 1.0% | 1 |
8 | ST ANDREA UNIV HOSP | 0 | 11% | 1.0% | 1 |
9 | INMMUNOL REUMATOL | 0 | 100% | 1.0% | 1 |
10 | OTA KU INTERNAL MED | 0 | 100% | 1.0% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000165511 | FK 506//FUJISAWA AMER//FUJISAWA AMER INC |
2 | 0.0000129868 | METHOTREXATE//METHOTREXATE POLYGLUTAMATES//MX 68 |
3 | 0.0000125210 | P GLYCOPROTEIN//C3435T POLYMORPHISM//ABCB1 |
4 | 0.0000122673 | ABATACEPT//TOCILIZUMAB//DISEASE MODIFYING ANTIRHEUMATIC DRUGS |
5 | 0.0000115414 | RHEUMATOL CONNECT TISSUE//COMMON RECEPTOR CHAIN//HLTH SCI B115 |
6 | 0.0000114235 | P GLYCOPROTEIN//MULTIDRUG RESISTANCE//PSC 833 |
7 | 0.0000097454 | CYP3A5//TACROLIMUS//CYTOCHROME P450 3A5 |
8 | 0.0000093788 | LEFLUNOMIDE//DIHYDROOROTATE DEHYDROGENASE//DG RHEUMATOL |
9 | 0.0000085287 | MAJOR VAULT PROTEIN//LUNG RESISTANCE RELATED PROTEIN//VPARP |
10 | 0.0000081692 | ABCG2//BCRP//BREAST CANCER RESISTANCE PROTEIN |